期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Drug delivery systems based on mesoporous silica nanoparticles for the management of hepatic diseases 被引量:1
1
作者 Boyan Liu Wenshi Liu +8 位作者 Miao Xu Tongyi Zhao Bingxin Zhou Ruilin Zhou Ze Zhu Xuchun Chen Zhiye Bao Keke Wang Heran Li 《Acta Pharmaceutica Sinica B》 2025年第2期809-833,共25页
The liver performs multiple life-sustaining functions.Hepatic diseases,including hepatitis,cirrhosis,and hepatoma,pose significant health and economic burdens globally.Along with the advances in nanotechnology,mesopor... The liver performs multiple life-sustaining functions.Hepatic diseases,including hepatitis,cirrhosis,and hepatoma,pose significant health and economic burdens globally.Along with the advances in nanotechnology,mesoporous silica nanoparticles(MSNs)exhibiting diversiform size and shape,distinct morphological properties,and favorable physico-chemical features have become an ideal choice for drug delivery systems and inspire alternative thinking for the management of hepatic diseases.Initially,we introduce the physiological structure of the liver and highlight its intrinsic cell types and correlative functions.Next,we detail the synthesis methods and physicochemical properties of MSNs and their capacity for controlled drug loading and release.Particularly,we discuss the interactions between liver and MSNs with respect to the passive targeting mechanisms of MSNs within the liver by adjusting their particle size,pore diameter,surface charge,hydrophobicity/hydrophilicity,and surface functionalization.Subsequently,we emphasize the role of MSNs in regulating liver pathophysiology,exploring their value in addressing liver pathological states,such as tumors and inflammation,combined with multi-functional designs and intelligent modes to enhance drug targeting and minimize side effects.Lastly,we put forward the problems,challenges,opportunities,as well as clinical translational issues faced by MSNs in the management of liver diseases. 展开更多
关键词 Mesoporous silica nanoparticles Drug delivery Hepatic diseases Surface modification msnseliver interactions Hepatocellular carcinoma BIOCOMPATIBILITY Liver disease treatment
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部